Cargando…

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV

Prostate specific membrane antigen (PSMA) is a specific high frequency cell surface marker of prostate cancers. Theranostic approaches targeting PSMA show no major adverse effects and rule out off-tumor toxicity. A PSMA-retargeted oHSV (R-405) was generated which both infected and was cytotoxic excl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vannini, Andrea, Parenti, Federico, Bressanin, Daniela, Barboni, Catia, Zaghini, Anna, Campadelli-Fiume, Gabriella, Gianni, Tatiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541339/ https://www.ncbi.nlm.nih.gov/pubmed/34696515 http://dx.doi.org/10.3390/v13102085

Ejemplares similares

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
por: Vannini, Andrea, et al.
Publicado: (2023)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
por: Petrovic, Biljana, et al.
Publicado: (2017)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
por: Petrovic, Biljana, et al.
Publicado: (2018)

αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
por: Vannini, Andrea, et al.
Publicado: (2019)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
por: Leoni, Valerio, et al.
Publicado: (2018)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells
por: Leoni, Valerio, et al.
Publicado: (2017)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

αvβ6- and αvβ8-Integrins Serve As Interchangeable Receptors for HSV gH/gL to Promote Endocytosis and Activation of Membrane Fusion
por: Gianni, Tatiana, et al.
Publicado: (2013)

The Epithelial αvβ3-Integrin Boosts the MYD88-Dependent TLR2 Signaling in Response to Viral and Bacterial Components
por: Gianni, Tatiana, et al.
Publicado: (2014)

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors
por: Gatta, Valentina, et al.
Publicado: (2015)

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
por: Jackson, Joseph W., et al.
Publicado: (2021)

Detection of circulating tumor cells using oHSV1‐hTERT‐GFP in lung cancer
por: Gao, Hongjun, et al.
Publicado: (2017)

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation
por: Swanner, Jessica, et al.
Publicado: (2023)

STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
por: Lee, Joel M., et al.
Publicado: (2019)

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
por: Sette, Paola, et al.
Publicado: (2019)

IM-4 Impact of oHSV activated NOTCH signaling in tumor microenvironment and its impact on anti-tumor immunity
por: Yoshihiro, Otani, et al.
Publicado: (2021)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
por: Zhang, Wen, et al.
Publicado: (2020)

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
por: De Lucia, Maria, et al.
Publicado: (2020)

Spotlight on… Gabriella Campadelli-Fiume
por: Campadelli-Fiume, Gabriella
Publicado: (2018)

A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4
por: Zhang, Wen, et al.
Publicado: (2015)

Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
por: Tuzmen, Ceren, et al.
Publicado: (2020)

Novel mutations in U(L)24 and gH rescue efficient infection of an HSV vector retargeted to TrkA
por: Marzulli, Marco, et al.
Publicado: (2023)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells
por: Lu, Ruitao, et al.
Publicado: (2021)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Endothelial Retargeting of AAV9 In Vivo
por: Bozoglu, Tarik, et al.
Publicado: (2022)

Retargeted adenoviruses for radiation-guided gene delivery
por: Kaliberov, S A, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kbthku4h2qgnthde4761poba7g